Integrative Analysis of Large-cell Lung Cancer (LCLC)

September 27, 2016 updated by: Da Fu, Shanghai 10th People's Hospital

Integrative Analysis of Large-cell Lung Carcinoma

Integrative analysis of LCLC

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Recruiting
        • Ganzhou City People's Hospital
        • Principal Investigator:
          • Xiaoming Zhong, MD
    • Shanghai
      • Shanghai, Shanghai, China, 200072
        • Recruiting
        • Shanghai Tenth People's Hospital
        • Contact:
        • Principal Investigator:
          • Yushui Ma, PhD
      • Shanghai, Shanghai, China, 200433
        • Recruiting
        • Shanghai Pulmonary Hospital
        • Contact:
          • Likun Hou, MD
          • Phone Number: 3030 00-86-21-65115006
          • Email: hlk9575@163.com
        • Principal Investigator:
          • Likun Hou, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with large-cell lung cancer

Description

Inclusion Criteria:

  • Age ≤ 75 years with histologically proven LCLC
  • No severe major organ dysfunction
  • World Health Organization (WHO) performance status of 0 or 1
  • No prior cancer chemotherapy

Exclusion Criteria:

  • Age ≥ 76
  • Severe major organ dysfunction
  • WHO performance status of >1
  • Prior cancer chemotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Normal lung tissue
Normal lung tissue from LCLC patients
Other: Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
LCLC tissues
LCLC tissues from LCLC patients
Other: Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
Metastasis tissues
Metastasis tissues from LCLC patients
Other: Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
5 years overall survival
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
5 years disease-free survival
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai 10th People's Hospital

Collaborators

Shanghai Pulmonary Hospital, Shanghai, China

Investigators

  • Principal Investigator: Da Fu, PhD, Shanghai 10th People's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Anticipated)

December 1, 2026

Study Completion (Anticipated)

December 1, 2026

Study Registration Dates

First Submitted

September 27, 2016

First Submitted That Met QC Criteria

September 27, 2016

First Posted (Estimate)

September 28, 2016

Study Record Updates

Last Update Posted (Estimate)

September 28, 2016

Last Update Submitted That Met QC Criteria

September 27, 2016

Last Verified

September 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016-52-Rainy

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The investigators are willing to share data.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Normal lung tissue

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe